# High blood sugar on PI3K, AKT and mTOR inhibitors: prevention, monitoring and treatment

Source: https://onco.cc/protocols/hyperglycaemia-on-pi3k-akt-mtor-inhibitors/  
OnCo record `hyperglycaemia-on-pi3k-akt-mtor-inhibitors` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Medicines that block PI3K, AKT or mTOR commonly raise blood sugar, often in the first weeks. Blood sugar and HbA1c are checked before and during treatment. Metformin is usually the first treatment, and the cancer medicine may be paused or its dose lowered. Tell your team at once about great thirst, passing a lot of urine, vomiting, confusion or trouble breathing. Your own team's plan comes first.

## Summary

Hyperglycaemia is an on-target effect of blocking insulin signalling through PI3K and AKT, and a labelled metabolic effect of mTOR inhibitors. The US labels report hyperglycaemia in 65% of patients on alpelisib (grade 3 in 33%, grade 4 in 3.9%), and raised fasting glucose in 85% on inavolisib, 37% on capivasertib with fulvestrant and 69% on capivasertib with abiraterone. The median time to onset was 15 days on alpelisib (events of grade 2 or higher), 15 days on capivasertib with fulvestrant, 71 days on capivasertib with abiraterone and 7 days on inavolisib. Ketoacidosis, including fatal cases, is in the alpelisib, capivasertib and inavolisib labels.

The alpelisib, capivasertib, inavolisib and gedatolisib labels ask for fasting glucose and HbA1c before starting, with glucose optimised first. The first three repeat HbA1c every 3 months; the gedatolisib label says at regular intervals and asks for glucose control before each infusion. Fasting glucose schedules differ by drug: alpelisib at least weekly for 2 weeks then at least every 4 weeks; inavolisib every 3 days in week 1, weekly to day 28, every 2 weeks for 8 weeks, then every 4 weeks; capivasertib on day 3 or 4 of the dosing week in weeks 1, 2, 4, 6 and 8, then monthly; everolimus before starting and annually in people without diabetes. The dose tables are written on fasting glucose: no change up to 160 mg/dL (8.9 mmol/L); above 160 to 250 mg/dL (8.9 to 13.9 mmol/L) capivasertib and inavolisib are withheld while alpelisib and gedatolisib continue; above 250 mg/dL (13.9 mmol/L) alpelisib, capivasertib and inavolisib are interrupted, and gedatolisib is withheld if a retest after hydration stays above 250 mg/dL; above 500 mg/dL (27.8 mmol/L) the drug is withheld and stopped for good if the value is confirmed on a recheck within 24 hours (alpelisib), if it persists at 24 hours or there are life-threatening effects (capivasertib), if it recurs within 30 days (inavolisib) or if it recurs (gedatolisib).

The labels do not set an order of glucose-lowering medicines, though the alpelisib label prints the metformin schedule used in SOLAR-1. Manufacturer-funded expert consensus (Gallagher 2024 for alpelisib, funded by Novartis; Iyengar 2025 for capivasertib, writing funded by AstraZeneca) puts metformin first and an SGLT2 inhibitor or a thiazolidinedione such as pioglitazone next. Iyengar advises ketone checks on an SGLT2 inhibitor; the Gallagher panel did not require them. Gallagher rates insulin and sulfonylureas as generally not appropriate first or second, noting a potential risk that insulin stimulates the PI3K pathway; the reviews by Tankova and by Goncalves and Farooki cite preclinical models in which insulin partly reactivated it; Iyengar advises avoiding insulin secretagogues because of hypoglycaemia. The UK JBDS and UK Chemotherapy Board guideline (2023), which is independent and covers all anticancer treatment, instead advises considering gliclazide 40 mg daily when plasma glucose is 12 mmol/L or more on two occasions and ruling out DKA or HHS at 20 mmol/L or more. No ESMO, ASCO or diabetes society guideline specific to these drugs was found.

## Fields

- Kind: Protocol
- Last checked: 2026-11-17
- Also known as: alpelisib hyperglycaemia; capivasertib hyperglycaemia; inavolisib hyperglycaemia; everolimus hyperglycaemia; PI3K inhibitor hyperglycemia; high blood sugar on Piqray; high blood sugar on Truqap; high blood sugar on Itovebi; treatment-induced hyperglycaemia; drug-induced diabetes on targeted therapy

## Connected records

- protocols: [Immune-related type 1 diabetes and diabetic ketoacidosis from checkpoint inhibitors](https://onco.cc/protocols/irae-diabetes/), [Iodinated contrast for CT: kidney function checks, kidney protection and metformin](https://onco.cc/protocols/iodinated-contrast-kidney-and-metformin/), [Raised cholesterol and triglycerides, and weight gain, on lorlatinib, bexarotene and elacestrant](https://onco.cc/protocols/raised-lipids-and-weight-gain-on-lorlatinib-bexarotene-and-elacestrant/)
- drugs: [Alpelisib](https://onco.cc/drugs/alpelisib/), [Capivasertib](https://onco.cc/drugs/capivasertib/), [Enfortumab vedotin](https://onco.cc/drugs/enfortumab-vedotin/), [Everolimus](https://onco.cc/drugs/everolimus/), [Gedatolisib](https://onco.cc/drugs/gedatolisib/), [Inavolisib](https://onco.cc/drugs/inavolisib/), [Temsirolimus](https://onco.cc/drugs/temsirolimus/)
- targets: [AKT](https://onco.cc/targets/akt/), [mTOR](https://onco.cc/targets/mtor/), [PIK3CA / PI3K-alpha](https://onco.cc/targets/pik3ca/)
- terms: [Hyperglycaemia (PI3K/AKT inhibitor class effect)](https://onco.cc/terms/hyperglycaemia/)

---
JSON: https://onco.cc/api/v1/entities/hyperglycaemia-on-pi3k-akt-mtor-inhibitors.json